Biosimilar Safety Surveillance: How Adverse Event Monitoring Works in 2026

Imagine you’re prescribed a life-saving biologic drug for rheumatoid arthritis or cancer. You’ve been stable on the original brand for years. Then, your insurance switches you to a biosimilar, which is a biological product highly similar to an already-approved reference biologic with no clinically meaningful differences in safety, purity, or potency. It’s cheaper. It works the same way. But because these drugs are complex molecules made in living cells-not simple chemical copies like generic ibuprofen-safety monitoring has to be razor-sharp. If something goes wrong, how do we know if it was the new biosimilar or just the underlying disease? This is where adverse event monitoring, also known as pharmacovigilance, becomes critical.

The stakes are high. As of 2023, Health Canada’s Canada Vigilance Program had processed over 1.2 million adverse reaction reports since 1965. Biosimilar-specific reports made up about 0.7% of total biologic drug reports in 2022. That small percentage hides a massive challenge: detecting rare but serious issues like immunogenicity, which is the body's immune response to a therapeutic protein, potentially reducing efficacy or causing allergic reactions. Unlike small-molecule generics, biosimilars cannot be identical to their reference products due to their complex manufacturing processes. This necessitates specialized surveillance systems to ensure patient safety while keeping healthcare costs down.

Why Biosimilars Need Specialized Safety Tracking

You might wonder why we can’t just treat biosimilars like generic pills. The answer lies in biology. A generic pill is a carbon copy of its brand-name counterpart. A biosimilar, however, is a ‘highly similar’ version of a reference biologic. Because biologics are large, complex proteins produced in living cells (like yeast or hamster ovary cells), slight variations in the manufacturing process can lead to minor structural differences. These differences usually don’t matter clinically, but they can sometimes trigger an immune response.

This is why immunogenicity monitoring is the cornerstone of biosimilar safety. If a patient develops antibodies against the drug, it might stop working or cause side effects. Dr. Thomas Lonngren, former Executive Director of the European Medicines Agency (EMA), emphasized in a 2019 White Paper that post-authorization safety monitoring must focus on immunogenicity as the primary potential differentiator between a biosimilar and its reference product.

Furthermore, traceability is a huge hurdle. In the U.S., the FDA approved unique four-letter suffixes for biosimilars starting in 2017 (e.g., ‘abp21’ for Amjevita). Health Canada requires brand name reporting. Without precise identification, it’s impossible to link an adverse event to the specific manufacturer. A 2022 survey of 1,247 U.S. physicians found that 63.4% reported confusion when documenting adverse events for biosimilars due to similar naming conventions. Hematologists and oncologists experienced the highest confusion rates at 81.7%.

How Safety Signals Are Detected: Spontaneous vs. Active Surveillance

Safety surveillance isn’t one-size-fits-all. Regulatory agencies use a dual-track system combining spontaneous reporting and active surveillance. Understanding the difference helps clarify how quickly problems are caught.

Spontaneous Reporting Systems (SRS) are the backbone of global pharmacovigilance. In the United States, serious adverse events must be reported within 15 calendar days, while non-serious ones have 90 days. Health Canada follows the same timeline under section C.01.016 of the Food and Drug Regulations. However, these systems rely on people remembering to report. Data from the IQVIA Institute in 2021 showed that biosimilar-specific reports represented only 0.3% of all biologic drug reports, despite biosimilars comprising 8.7% of prescriptions. This suggests significant underreporting.

To plug this gap, regulators use Active Surveillance (AS). The FDA’s Sentinel Initiative, launched in 2008, analyzes millions of electronic health records and insurance claims to proactively identify safety signals. For example, if a spike in infusion reactions appears among patients using a specific biosimilar lot, Sentinel can flag it before hundreds more patients are affected. The EMA launched an AI-powered signal detection system called VigiLyze in 2022, which processes 1.2 million new case reports annually with 92.4% accuracy.

Regulatory Differences: EMA vs. FDA vs. Health Canada

Not all countries monitor biosimilars the same way. While the goal-patient safety-is universal, the methods vary. This fragmentation can complicate global drug development and safety tracking.

In the European Union, the EMA operates under guidelines established in 2013. They require all biological medicines, including biosimilars, to follow the same pharmacovigilance framework. The EMA states there are no ‘specific safety requirements applicable only to biosimilars because of their different development route.’ Instead, they rely on robust general biologics monitoring.

Health Canada takes a more explicit approach. Their 2022 Handbook for Health Care Professionals mandates that Risk Management Plans (RMPs) for biosimilars must include detailed information on how immunogenicity will be monitored. Crucially, it requires a discussion on methods to distinguish adverse event reports for the biosimilar from those for other licensed products. On January 1, 2023, Health Canada implemented new traceability requirements mandating clear identification of the specific manufacturer in all adverse event reports, with non-compliance penalties up to CAD$500,000.

The United States FDA uses a hybrid model. Biosimilar manufacturers must submit Periodic Safety Update Reports (PSURs) every six months for the first two years post-approval, then annually. The 21st Century Cures Act (2016) mandated bi-weekly screening of the Adverse Event Reporting System database. In 2023, the FDA released draft guidance for ‘interchangeable’ biosimilars, introducing enhanced requirements including mandatory post-marketing studies to assess switching effects.

The Traceability Crisis: Why Naming Matters

One of the biggest practical challenges in biosimilar safety is knowing exactly which product caused an issue. When multiple biosimilars target the same reference product (like trastuzumab or adalimumab), confusion is inevitable without strict naming conventions.

In Spain, mandatory biosimilar identification in electronic health records was implemented in 2020. Pharmacist Maria Fernandez from Barcelona reported that adverse event reporting accuracy for biosimilars improved from 58% to 92% after this change. Contrast this with the U.S., where a 2022 HIMSS survey found that only 42.6% of hospitals had fully implemented capabilities to capture the specific manufacturer and product name in electronic health records.

Patient advocacy groups highlight the human cost of this ambiguity. The Arthritis Foundation’s 2022 Patient Safety Survey found that 41.2% of respondents treated with biosimilars were unsure which specific product they received. If a patient has a severe reaction, not knowing the exact manufacturer hinders both treatment adjustment and regulatory signal detection.

Future Trends: AI, Real-World Evidence, and Global Harmonization

The landscape of biosimilar safety surveillance is evolving rapidly. With the global biosimilars market projected to reach $34.9 billion by 2028, scalable and intelligent monitoring systems are no longer optional-they’re essential.

Artificial Intelligence and Machine Learning are becoming standard tools. The Strategic Pharmacovigilance Checklist for Biosimilar Safety (2025) recommends using AI to improve risk assessment and signal processing. Natural language processing tools can analyze unstructured clinical notes to detect subtle patterns that traditional coding might miss. For mid-sized pharmaceutical companies, integrating these tools typically costs between $250,000 and $500,000 and takes 4-6 months.

Real-World Evidence (RWE) is gaining prominence. According to a 2022 Biotechnology Innovation Organization survey, 78.3% of biosimilar manufacturers are investing in active surveillance systems beyond traditional spontaneous reporting. This shift allows regulators to see how drugs perform in diverse, real-world populations, not just controlled trial settings.

Global Harmonization efforts are underway through the International Council for Harmonisation (ICH). The ICH E2C(R2) guideline for PSUR templates, effective since July 2016, is now adopted by 54 regulatory authorities worldwide. Looking ahead, the International Pharmaceutical Regulators Programme (IPRP) is proposing a global unique device identifier (UDI)-like system for biologics by 2026. Pilot studies in Switzerland suggest this could reduce adverse event attribution errors by 73.5%.